The Limits of Big Data

This morning in a press release Lilly (NYSE: LLY) stated;

“In an effort to improve health outcomes of people with type 2 diabetes, Geisinger and Boehringer Ingelheim, on behalf of its diabetes alliance with Eli Lilly and Company (NYSE: LLY), today announced a major collaboration to develop a risk-prediction model for three critical health outcomes commonly associated with type 2 diabetes that have long-term impact and cost-of-care implications: cardiovascular death, kidney failure and hospitalization for heart failure.

The new model will allow healthcare professionals to predict which adults with type 2 diabetes are most at risk . . .

This content is restricted to subscribers. Please subscribe.

Already have an account? Please login.

This entry was posted in Email Alerts. Bookmark the permalink.